tradingkey.logo

Dynavax Technologies Corp

DVAX
15.380USD
+4.250+38.19%
收盤 12/24, 13:00美東報價延遲15分鐘
1.81B總市值
虧損本益比TTM

Dynavax Technologies Corp

15.380
+4.250+38.19%

關於 Dynavax Technologies Corp 公司

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

Dynavax Technologies Corp簡介

公司代碼DVAX
公司名稱Dynavax Technologies Corp
上市日期Feb 19, 2004
CEOSpencer (Ryan)
員工數量405
證券類型Ordinary Share
年結日Feb 19
公司地址2100 Powell Street
城市EMERYVILLE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編94608
電話15108485100
網址https://www.dynavax.com/
公司代碼DVAX
上市日期Feb 19, 2004
CEOSpencer (Ryan)

Dynavax Technologies Corp公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Ryan Spencer
Mr. Ryan Spencer
Chief Executive Officer, Director
Chief Executive Officer, Director
277.67K
--
Dr. Robert (Rob) Janssen, M.D.
Dr. Robert (Rob) Janssen, M.D.
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
74.92K
--
Mr. David F. Novack
Mr. David F. Novack
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
56.05K
+33.36%
Mr. John L. Slebir
Mr. John L. Slebir
Senior Vice President, General Counsel
Senior Vice President, General Counsel
31.42K
--
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
29.86K
+23.89%
Ms. Kelly MacDonald, CPA
Ms. Kelly MacDonald, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
25.52K
--
Dr. Peter R. Paradiso, Ph.D.
Dr. Peter R. Paradiso, Ph.D.
Independent Director
Independent Director
24.83K
+30.19%
Dr. Daniel L. (Dan) Kisner, M.D.
Dr. Daniel L. (Dan) Kisner, M.D.
Independent Director
Independent Director
23.33K
+32.77%
Mr. Brent MacGregor
Mr. Brent MacGregor
Independent Director
Independent Director
21.83K
+35.83%
Dr. Emilio Emini
Dr. Emilio Emini
Independent Director
Independent Director
1.44K
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Ryan Spencer
Mr. Ryan Spencer
Chief Executive Officer, Director
Chief Executive Officer, Director
277.67K
--
Dr. Robert (Rob) Janssen, M.D.
Dr. Robert (Rob) Janssen, M.D.
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
74.92K
--
Mr. David F. Novack
Mr. David F. Novack
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
56.05K
+33.36%
Mr. John L. Slebir
Mr. John L. Slebir
Senior Vice President, General Counsel
Senior Vice President, General Counsel
31.42K
--
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
29.86K
+23.89%
Ms. Kelly MacDonald, CPA
Ms. Kelly MacDonald, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
25.52K
--

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
業務USD
名稱
營收
佔比
HEPLISAV-B
91.87M
96.26%
Other revenue
3.57M
3.74%
地區USD
名稱
營收
佔比
US
93.57M
98.04%
Non-US
1.88M
1.96%
業務
地區
業務USD
名稱
營收
佔比
HEPLISAV-B
91.87M
96.26%
Other revenue
3.57M
3.74%

股東統計

更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Deep Track Capital LP
13.39%
BlackRock Institutional Trust Company, N.A.
12.52%
The Vanguard Group, Inc.
6.88%
State Street Investment Management (US)
5.35%
Millennium Management LLC
3.86%
其他
58.00%
持股股東
持股股東
佔比
Deep Track Capital LP
13.39%
BlackRock Institutional Trust Company, N.A.
12.52%
The Vanguard Group, Inc.
6.88%
State Street Investment Management (US)
5.35%
Millennium Management LLC
3.86%
其他
58.00%
股東類型
持股股東
佔比
Investment Advisor
36.25%
Hedge Fund
33.74%
Investment Advisor/Hedge Fund
21.02%
Research Firm
6.07%
Pension Fund
1.18%
Individual Investor
0.60%
Bank and Trust
0.40%
Private Equity
0.04%
Sovereign Wealth Fund
0.03%
其他
0.67%

機構持股

更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
546
115.83M
109.38%
+66.95K
2025Q3
565
115.78M
113.44%
+813.17K
2025Q2
563
116.95M
120.36%
-13.51M
2025Q1
558
131.20M
118.77%
-16.39M
2024Q4
550
133.28M
116.08%
-4.50M
2024Q3
545
132.56M
115.53%
-2.40M
2024Q2
531
134.71M
114.10%
-1.03M
2024Q1
527
135.87M
107.19%
-4.14M
2023Q4
514
128.04M
106.45%
-253.89K
2023Q3
500
128.23M
106.72%
-886.82K
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Deep Track Capital LP
15.73M
13.41%
-2.07M
-11.61%
Aug 22, 2025
BlackRock Institutional Trust Company, N.A.
15.80M
13.47%
-2.85M
-15.27%
Jun 30, 2025
The Vanguard Group, Inc.
8.40M
7.17%
-266.13K
-3.07%
Jun 30, 2025
State Street Investment Management (US)
6.40M
5.45%
-394.51K
-5.81%
Jun 30, 2025
Millennium Management LLC
1.61M
1.38%
+1.39M
+612.12%
Jun 30, 2025
Chicago Capital, LLC
5.23M
4.46%
-116.66K
-2.18%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
3.64M
3.11%
-365.20K
-9.11%
Jun 30, 2025
Renaissance Technologies LLC
2.89M
2.46%
+181.00K
+6.69%
Jun 30, 2025
Two Sigma Investments, LP
3.80M
3.24%
+1.53M
+67.74%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.69M
2.29%
-377.05K
-12.30%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Invesco Biotechnology & Genome ETF
2.91%
Virtus LifeSci Biotech Products ETF
1.58%
ETC 6 Meridian Small Cap Equity ETF
1.21%
Invesco S&P SmallCap Health Care ETF
0.62%
ETC 6 Meridian Low Beta Equity Strategy ETF
0.46%
Pacer US Small Cap Cash Cows Growth Leaders ETF
0.42%
State Street SPDR S&P Biotech ETF
0.41%
Themes US Small Cap Cash Flow Champions ETF
0.35%
Royce Quant Small-Cap Quality Value ETF
0.29%
Direxion Daily S&P Biotech Bull 3X Shares
0.25%
查看更多
Invesco Biotechnology & Genome ETF
佔比2.91%
Virtus LifeSci Biotech Products ETF
佔比1.58%
ETC 6 Meridian Small Cap Equity ETF
佔比1.21%
Invesco S&P SmallCap Health Care ETF
佔比0.62%
ETC 6 Meridian Low Beta Equity Strategy ETF
佔比0.46%
Pacer US Small Cap Cash Cows Growth Leaders ETF
佔比0.42%
State Street SPDR S&P Biotech ETF
佔比0.41%
Themes US Small Cap Cash Flow Champions ETF
佔比0.35%
Royce Quant Small-Cap Quality Value ETF
佔比0.29%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.25%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Dynavax Technologies Corp的前五大股東是誰?

Dynavax Technologies Corp的前五大股東如下:
Deep Track Capital LP
持有股份:15.73M
佔總股份比例:13.41%。
BlackRock Institutional Trust Company, N.A.
持有股份:15.80M
佔總股份比例:13.47%。
The Vanguard Group, Inc.
持有股份:8.40M
佔總股份比例:7.17%。
State Street Investment Management (US)
持有股份:6.40M
佔總股份比例:5.45%。
Millennium Management LLC
持有股份:1.61M
佔總股份比例:1.38%。

Dynavax Technologies Corp的前三大股東類型是什麼?

Dynavax Technologies Corp 的前三大股東類型分別是:
Deep Track Capital LP
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.

有多少機構持有Dynavax Technologies Corp(DVAX)的股份?

截至2025Q4,共有546家機構持有Dynavax Technologies Corp的股份,合計持有的股份價值約為115.83M,占公司總股份的109.38% 。與2025Q3相比,機構持股有所增加,增幅為-4.05%。

哪個業務部門對Dynavax Technologies Corp的收入貢獻最大?

在FY2025Q2,HEPLISAV-B業務部門對Dynavax Technologies Corp的收入貢獻最大,創收91.87M,占總收入的96.26% 。
KeyAI